Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

Autor: G.M. Kenny, V.A. Bowes, Gerald P. Murphy, Alton L. Boynton, Abdel-Aziz A. Elgamal, J. Jarisch, M. Rogers, R.C. Ireton, Haakon Ragde, Oliver E. Cobb, M.J. Troychak, S.J. Simmons, Michael L Salgaller, Benjamin A. Tjoa
Rok vydání: 1999
Předmět:
Zdroj: The Prostate. 38:73-78
ISSN: 1097-0045
0270-4137
Popis: BACKGROUND A phase II trial was conducted to assess the efficacy of infusions of dendritic cells (DC) and two HLA-A2-specific PSMA peptides (PSM-P1 and -P2). This report describes thirty three subjects with hormone-refractory metastatic prostate cancer without prior vaccine therapy history who were evaluated and reported as a group. METHODS All subjects received six infusions of DC pulsed with PSM-P1 and -P2 at six week intervals. Clinical monitoring was conducted pre-, during, and post- phase II study. Data collected include: complete blood count, bone and total alkaline phosphatase, prostate markers, physical examination, performance status, bone scan, ProstaScint® scan, chest x-ray, as well as assays to monitor cellular immune responses. RESULTS Six partial and two complete responders were identified in the phase II study based on NPCP criteria, plus 50% reduction of prostate-specific antigen (PSA), or resolution in previously measurable lesions on ProstaScint® scan. CONCLUSIONS Over 30% of study participants in this group showed a positive response at the conclusion of the trial. This study suggested that DC-based cancer vaccines may provide an alternative therapy for prostate cancer patients whose disease no longer responds to hormone therapy. Prostate 38:73–78, 1999. © 1999 Wiley-Liss, Inc.
Databáze: OpenAIRE
Externí odkaz: